Navigation Links
Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcano's VH(R) IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks
Date:9/24/2009

therapy. The negative predictive accuracy of VH(R) IVUS is very similar to Fractional Flow Reserve (FFR) in its potential to reduce procedure costs by stenting only the patients and lesions that will benefit from that therapy."

Evening Symposium

To explore the imaging data in greater detail, Volcano will host an evening symposium entitled, "Imaging Matters! Identifying high risk patients and optimizing PCI." The symposium will include late breaking results from PROSPECT, FAME and other clinical studies. The first session of the symposium, entitled, "Can imaging help identify at-risk vulnerable plaques and patients before catastrophe (or those not at risk)," will feature presentations from Patrick W. Serruys, M.D., Gary S. Mintz, M.D., Gregg W. Stone, M.D. and Alexandra Lansky, M.D. The second session, entitled, "Ischemia, FFR and Optimal Revascularization," will include presentations by Gregg W. Stone, M.D., Bernard de Bruyne, M.D., PhD, Bill Fearon, M.D. and Mort Kern, M.D. The event will be held at the Hilton San Francisco in the Imperial Room on Thursday, September 24. A reception will be held from 7:00 PM - 8:00 PM, followed by the symposium from 8:00 PM - 10:00 PM.

About the PROSPECT Trial

Abbott's PROSPECT trial is the first prospective natural history study to examine the role of vulnerable plaque and how it might progress to a cardiac event. PROSPECT used novel intravascular imaging technology to correlate plaque characteristics, patient risk factors and biomarker measurements with subsequent heart attacks and other cardiac events, potentially paving the way for physicians to identify and treat at-risk patients before a heart attack occurs.

PROSPECT enrolled 700 patients from 40 clinical centers across the United States and Europe. All patients received PCI for acute coronary syndrome (ACS), which included unstable angina, NSTEMI or STEMI. Patient f
'/>"/>

SOURCE Volcano Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Video: New Clinical Trial Results Show Germ-Killing Action of LISTERINE(R) Antiseptic Kills Germs in the Mouth Before They Travel to the Bloodstream
2. Volcano Corporation Praises FAME Study Results
3. Dynatronics to Release Fourth Quarter and Year-end Results Friday, September 25, 2009; Conference Call Set for 12:30 p.m. ET
4. InVitria Presents Zap-CHO Performance Results at PEACe Conference
5. Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results
6. Assurant to Announce 2009 Third Quarter Results Oct. 28, 2009 and Host Webcast Conference Call Oct. 29
7. SpectraScience Announces Results of Annual Shareholder Meeting
8. One-year results from Horizons-AMI trial reported at TCT 2009
9. New type of sirolimus-eluting stent demonstrates superior results
10. Details Emerge About Approach, Results of First US Face Transplant
11. Instrumentation Laboratory Announces Passion & Results Award Winners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... mounts showing the potential health benefits of probiotics, antioxidants ... taking supplements. And the chemical industry is getting in ... effects could deter growth, so the industry is responding ... to the cover story in Chemical & Engineering ... American Chemical Society. , Melody M. Bomgardner, a senior ...
(Date:4/23/2014)... for-profit and non-profit organizations in Washington will receive ... Concept grants to accelerate maturation of promising health-related ... Sciences Discovery Fund (LSDF) announced today. Also announced ... the Washington Biotechnology & Biomedical Association (WBBA) to ... next generation of entrepreneurs and help early-stage companies ...
(Date:4/23/2014)... Physical Activity on Mobility Limitation in Old Age , ... of mobility limitation in old age, whereas leisure-time physical ... study which followed up 5,200 public sector employees for ... Research Center in Finland and the Finnish Institute of ... wears the body and lasts for several hours a ...
(Date:4/23/2014)... studies have shown that proliferation of endogenous neural ... to neurons and axons. From the perspective of ... Sun Yat-sen University in China observed the effects ... precursor cell proliferation and expression of basic fibroblast ... rat brain on the infarct side. The researchers ...
(Date:4/22/2014)... visited the New Jersey Institute of Technology (NJIT) ... for the launch of the New Jersey Innovation ... new model for business innovation through the leveraging ... investment. U.S. Senator Cory Booker, Panasonic Corp. of ... Jersey Lieutenant Governor Kim Guadagno, New Jersey Secretary ...
Breaking Medicine News(10 mins):Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2
... symptoms showed dramatic improvements with fish oil supplements in ... ran a trial on 25 teenagers who had been ... with a combination of omega-3 fish and omega-6 evening ... ,94% of these students aged 12 to 15 ...
... study conducted by Jiahai Lu, Ph.D., of the school ... passive immunotherapy// is the best way to treat highly ... uses antibodies from horses. Purified antibodies to the ... were used against mice and it proved effective in ...
... Jalgaon is in the eye of the storm once ... of Jalgaon district in Maharashtra. Following the bird-flu notification// ... week of March, samples were sent to High Security ... seven samples had tested positive for the H5 virus. ...
... nanotechnology has been developed at Leeds that will benefit ... surgery and for the next generation// of miniaturized computers. ... Professor Richard Williams and Dr Yulong Ding have created ... than other liquids. In a central heating system, nanofluids ...
... Pacific Islands, which consists of the some of the ... global conservation map//, and is said to be the ... ,Martin Puta Tofinga, Minister of Environment, Lands ... the establishment of the Phoenix Islands Protected Area at ...
... of Food Technology magazine designer foods and functional ... mention of micro and macro nutrients// nanonutrients are ... in nanotechnology show great potential for positively influencing ... facilitating the controlled release and protecting the stability ...
Cached Medicine News:Health News:Passive Immunotherapy Could Prevent Avian Flu from Affecting Humans 2Health News:Phoenix Islands To Be Protected Under Global Conservation Map 2Health News:Phoenix Islands To Be Protected Under Global Conservation Map 3
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... new survey shows almost half (44%) of U.S. patients ... acute pain. (Logo: http://photos.prnewswire.com/prnh/20110816/DC52192LOGO-b ) ... Pain (P3) Survey, one of the largest pain management ... also show that this undertreatment was particularly prevalent among ...
... 2011 Cohera Medical, Inc.®, a rapidly growing medical ... Mark approval for its lead product, TissuGlu® ... to be sold in the European Union. ... large flap surgeries, such as abdominoplasties, that helps reduce ...
Cached Medicine Technology:New Survey Shows Moderate-to-Severe Acute Pain is Widely Undertreated, Especially Among Older Adults 2Cohera Medical Receives CE Mark Approval for TissuGlu® Surgical Adhesive 2Cohera Medical Receives CE Mark Approval for TissuGlu® Surgical Adhesive 3
Cuffed pediatric endotracheal tubes, available from 2.5 mm to 4.5 mm inside diameter. Ruschelit® PVC. Magill tip - nasoral. X-ray opaque line. Graduated. Single use. Sterile...
... Ruschelit® PVC. Murphy eye-oral. High ... Graduated. Oral Cuffed Single use. For ... kinking of the tube by incorporating ... low-pressure cuff. Thermosensitive Ruschelit® PVC adapts ...
... Clear Plus™ Cuffed Endotracheal Tube w. Flexi -Slip™ ... Single use. A quality Rusch endotracheal tube with ... saving you time and storage space. The stylet ... withdrawal. It is designed with a soft distal ...
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. No cuff.Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Sterile...
Medicine Products: